Last month, the Food and Drug Administration (FDA) announced that it was investigating cases of pancreatitis and precancerous cellular changes called pancreatic duct metaplasia in patients taking a class of type 2 diabetes drugs known as incretin mimetics. Lawsuits against manufacturers of several of these drugs have been underway for years.
Incretin mimetic drugs include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).
The FDA’s inquiry is based on unpublished findings from a group of academic researchers who examined a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes.
Byetta lawsuits and Januvia lawsuits involving thyroid cancer and pancreatic cancer are currently being tried, and Byetta lawsuits alleging pancreatitis have already been settled in California.
For Januvia cases in particular, patients must have been diagnosed with acute, chronic pancreatitis, not just pancreatitis. Januvia patients who have been diagnosed with hyperthyroidism may not have a lawsuit, but should be monitored on a regular basis because the condition could develop into thyroid cancer.
The first lawsuits against the type 2 diabetes drug Actos and bladder cancer will soon be tried in Chicago. Patients who have developed bladder cancer after taking Actos should consult with an attorney as soon as possible because the statute of limitations will soon run out. Actos is in a different class of diabetes drugs known as thiazolidinediones, or TZDs. Another TZD, Avandia, was severely restricted by the FDA in 2010 after it was linked to fatal heart attacks.
Source: Lawyers and Settlements